# Investor Data Room > AIRCHILL investor due-diligence hub with a public document register, current product and regulatory status, evidence boundaries, closing conditions, risks and controlled-access materials. - Canonical: https://www.medicalcooling.com/investor-data-room/ - Markdown: https://www.medicalcooling.com/investor-data-room/index.md - Language: de-DE - Last modified: 2026-08-14T22:41:14+00:00 AIRCHILL · Investor Data Room Development-stage · no CE mark · no FDA clearance · not for patient use Last reviewed 15 August 2026 · [Trust Center / change history](https://www.medicalcooling.com/trust-center/) # Due diligence should be easier than the pitch. A structured diligence hub for Medical Cooling / AIRCHILL covering product, evidence, intellectual property, regulatory strategy, reimbursement, market, financial planning, execution risks and the materials that remain restricted or incomplete. [Read Investor Snapshot →](https://www.medicalcooling.com/investor-snapshot/)[Open document register ↓](#register)[Request restricted materials](https://www.medicalcooling.com/contact/) ### Current financing frame Current round€7.5m planning case Runway30 months Follow-on after Gate B€10–15m indicative First patientPlanned 2029 Base-case revenue to 2031€0 Public diligence layerEvidence, market, regulatory and source registers are directly reviewable. Restricted deal materialsInvestor deck, financial model and formal transaction documents are shared selectively. Gaps are labelledMissing or unfinished diligence items are not disguised as complete. Development-stageNo representation of regulatory approval or established clinical efficacy. Room map ## Eight diligence workstreams. The room is organised the way a professional MedTech diligence process usually unfolds: company and transaction first, then product, evidence, IP, regulatory, market access, financials and execution risk. [01Company & transaction](#company)[02Product & engineering](#product)[03Clinical & evidence](#clinical)[04IP & freedom to operate](#ip)[05Regulatory & QMS](#regulatory)[06Market & reimbursement](#market)[07Financial & fundraising](#financial)[08Risks & closing conditions](#risk) Master document register ## What exists, what is restricted, and what is still a gap. “Available” means a diligence source is currently published on MedicalCooling.com or in an official public register. “Restricted” means the existing material is described by the company but is not published here. “Gap” means the current public materials explicitly identify the item as unresolved or not yet documented. # Document / workstream Scope Status 01.1 [Investor & funding overview ↗](https://www.medicalcooling.com/investors/) Round size, runway, use of funds, milestones, market logic, business model, IP position and disclosed diligence risks. Available 01.2 [Legal notice / operator ↗](https://www.medicalcooling.com/legal-notice/) Public operator and legal identity information for the website/project. Available 01.3 Cap table, shareholder rights & financing history Not contained in the current public investor materials. Restricted / request 01.4 Corporate documents & board/shareholder approvals Transaction-level corporate records; not published on the public site. Restricted / request 02.1 [AIRCHILL product overview ↗](https://www.medicalcooling.com/airchill/) Development-stage product concept, intended workflow, architecture and product positioning. Available 02.2 Design history / requirements / verification package Formal controlled design records and verification outputs required for technical diligence. In preparation 02.3 Risk management file & usability engineering ISO 14971 / IEC 62366-oriented controlled records are not represented as complete in the public materials. In preparation 03.1 [AIRCHILL evidence overview ↗](https://www.medicalcooling.com/evidence/) Conservative separation of mechanism data, clinical context, AIRCHILL-specific findings and evidence gaps. Available 03.2 [Hypothermia research register ↗](https://www.medicalcooling.com/research-register/) Research map, evidence levels, thermal-dose context, key study families and ongoing trials. Available 03.3 [Clinical study planner ↗](https://www.medicalcooling.com/clinical-study-planner/) Scenario planning for sample size, recruitment, follow-up, power and budget sensitivity. Available 03.4 First-in-patient protocol package Gate B is planned for 2029; protocol, sites, approvals and final endpoints are not represented as complete. In preparation 04.1 [EP3509683B1 ↗](https://patents.google.com/patent/EP3509683B1/en) Granted European patent; public register record. Available 04.2 [US11395900B2 ↗](https://patents.google.com/patent/US11395900B2/en) Granted US patent; public register record. Available 04.3 Founder-controlled IP transfer / exclusive licence Both granted patents are held solely by founder and inventor Fabian Temme. The university is no longer part of the patent ownership structure, so there is no institutional co-owner to negotiate with. Assignment or an exclusive licence to the operating company can be documented directly with the sole patent holder as a defined financing step. Structured closing step 04.4 FTO, claim-scope, validation-state & annuity review The public investor material explicitly states these have not yet been assessed. Gap 05.1 [Regulatory & reimbursement planning ↗](https://www.medicalcooling.com/regulatory-reimbursement/) Preliminary classification, regulatory pathway and reimbursement assumptions. Available 05.2 Formal regulatory classification rationale The investor materials describe Class IIb as preliminary rather than established. In preparation 05.3 QMS implementation plan / certification evidence The current round allocates funds to QMS and regulatory affairs; no completed certification is claimed. In preparation 06.1 [Global EMS reimbursement atlas ↗](https://www.medicalcooling.com/global-reimbursement-atlas/) Cross-market payer, ambulance-funding, procurement and innovation-pathway research. Available 06.2 [Germany EMS district atlas ↗](https://www.medicalcooling.com/germany-ems-reimbursement-district-atlas/) District-level reimbursement, responsible bodies, payer logic and procurement roles. Available 06.3 [Global impact atlas & models ↗](https://www.medicalcooling.com/global-impact-models/) Evidence-labelled impact scenarios and transparent modelling assumptions. Available 06.4 Customer discovery / signed LOIs / procurement interviews No public claim of completed commercial validation or committed customers is made in the current investor materials. Gap / request evidence 07.1 2027–2031 financial model The investor page states that low, base and high cases exist and that base-case commercial revenue through 2031 is €0. Restricted 07.2 Business plan — venture version Existing according to the investor page; not published. Restricted 07.3 Business plan — bank / development-bank versions Existing according to the investor page; not published. Restricted 07.4 Bank statements, debt, grants & committed financing evidence The public investor material states that opening liquidity, debt and non-committed grants are set to €0 until documentary evidence exists. Restricted / documentary 08.1 [Sources, assumptions & data gaps ↗](https://www.medicalcooling.com/sources-assumptions/) Site-wide source directory and explicit register of assumptions, derived values, proxies and missing data. Available 08.2 Founder capacity & employment/IP terms The public investor material states weekly hours, compensation, transition date and secondary-employment/IP terms are not yet documented. Gap 08.3 [Legal & information disclaimer ↗](https://www.medicalcooling.com/disclaimer/) Boundaries around medical, regulatory, fundraising and model information. Available Data-room rule: Nothing is marked “Available” because it sounds likely to exist. Public links are only used where a reviewable source is currently present. Restricted items are described only where the existing investor material says they exist; unresolved items remain explicit gaps. Fast diligence paths ## Open the evidence behind the investment case. These are the highest-signal public paths for a first investor review before requesting confidential transaction documents. Product ### AIRCHILL Understand the development-stage platform, system thesis and intended emergency-care workflow. [Open →](https://www.medicalcooling.com/airchill/) Science ### Evidence register Review what the project supports, what belongs only to the broader literature and what still needs validation. [Open →](https://www.medicalcooling.com/evidence/) Clinical ### Research register Inspect the broader hypothermia evidence landscape and ongoing trial context. [Open →](https://www.medicalcooling.com/research-register/) Regulatory ### Regulatory pathway Review current planning assumptions without treating them as granted classification or approval. [Open →](https://www.medicalcooling.com/regulatory-reimbursement/) Market access ### EMS reimbursement Review payer, procurement and reimbursement structures instead of relying on a generic TAM slide. [Open →](https://www.medicalcooling.com/global-reimbursement-atlas/) Audit trail ### Sources & assumptions Trace modelling inputs, transferred sensitivities and known data gaps. [Open →](https://www.medicalcooling.com/sources-assumptions/) Key diligence flags ## Material issues already surfaced before an investor asks. These are not hidden in footnotes. They are the issues most likely to affect valuation, closing conditions or the next value-inflection milestone. Founder-controlled IP ### Concentrated ownership simplifies the corporate IP step The granted European and US patents are held solely by founder and inventor Fabian Temme. The university is no longer part of the patent ownership structure, avoiding institutional co-ownership and multi-party negotiations. The remaining step is a direct assignment or exclusive, worldwide, sublicensable licence from the sole patent holder to the operating company as part of the financing structure. Evidence risk ### Clinical benefit is not established The existing evidence section explicitly distinguishes mechanism and technical findings from future clinical efficacy. Prior airway-cooling trials in the field are part of the risk context. Regulatory ### Class IIb remains preliminary The public investor material does not present the classification as final and allocates material funding to QMS, regulatory affairs and verification/validation. Execution ### Founder-capacity terms need documentation The investor material states that weekly hours, compensation, transition date and employment/IP terms are not yet documented. Restricted vault ## Confidential materials belong behind controlled access. The public room is deliberately not a file dump. Transaction-sensitive documents should move into a controlled-access vault with named investor access, NDA status, document versioning and a download/audit trail. [Request data-room access →](https://www.medicalcooling.com/contact/)[Review funding overview](https://www.medicalcooling.com/investors/) No password, cap table, bank document, investor deck, financial workbook or personal employment document is published on this page. - 01Investor deck 2026 - 022027–2031 financial model · low / base / high - 03Venture, bank and development-bank business plans - 04Cap table / financing history / transaction documents - 05IP assignment or licence documentation once executed - 06Corporate, employment and board/shareholder materials - 07Controlled technical/QMS records as they mature Investor access ## Start with the public evidence. Request the restricted room when the fit is real. The objective is a faster, cleaner diligence process: fewer unsupported claims, fewer hidden surprises and a clear distinction between public evidence, confidential documents and unresolved work. [Request restricted access](https://www.medicalcooling.com/contact/)[Investor overview](https://www.medicalcooling.com/investors/) AIRCHILL is a development-stage medical technology project. This data room does not represent regulatory approval, established clinical efficacy, a securities offering or a guarantee of future financing or performance.